GlaxoSmithKline derma acquisitions
This article was originally published in The Rose Sheet
Executive Summary
Consumer Healthcare division acquires five Rx dermatology products from Elan Pharmaceuticals to complement existing OTC portfolio, which includes Oxy acne products and Abreva cold sore medication, GlaxoSmithKline says. Pharmaceutical additions include Aclovate, Cutivate and Temovate, primarily recommended to stop itching, swelling and redness associated with skin conditions, Oxistat, an anti-fungal medication, and Emgel, an anti-acne treatment. Five products generated sales of $35 mil. in first six months of 2002 and revenues of $62 mil. in 2001, according to firm. Elan Pharmaceuticals is exiting the dermatology business...